Though there are many elements in the tumor microenvironment that favor a pro or anti-cancer response, we now understand that the success of many approved cancer therapies ultimately depends on the sustained activation of TAA-specific CD8+ T cells through DCs9,11,12. This evidence concerns the gene CD8A and neoplasm.